These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21894562)

  • 21. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients.
    Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Ann Surg Oncol; 2012 Sep; 19(9):3107-15. PubMed ID: 22451234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Expression of Slit2 and Robo1 is Associated with Poor Prognosis and Brain-specific Metastasis of Breast Cancer Patients.
    Qin F; Zhang H; Ma L; Liu X; Dai K; Li W; Gu F; Fu L; Ma Y
    Sci Rep; 2015 Sep; 5():14430. PubMed ID: 26400100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
    Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
    PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.
    Seniski GG; Camargo AA; Ierardi DF; Ramos EA; Grochoski M; Ribeiro ES; Cavalli IJ; Pedrosa FO; de Souza EM; Zanata SM; Costa FF; Klassen G
    BMC Cancer; 2009 Mar; 9():80. PubMed ID: 19267929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated.
    Qiu H; Zhu J; Yu J; Pu H; Dong R
    Asian Pac J Cancer Prev; 2011; 12(3):791-5. PubMed ID: 21627385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
    Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
    Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
    Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
    Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of RUNX3 inactivation in columnar cell lesions of breast.
    Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
    Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.
    Astuti D; Da Silva NF; Dallol A; Gentle D; Martinsson T; Kogner P; Grundy R; Kishida T; Yao M; Latif F; Maher ER
    Br J Cancer; 2004 Jan; 90(2):515-21. PubMed ID: 14735202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
    Park SY; Seo AN; Jung HY; Gwak JM; Jung N; Cho NY; Kang GH
    PLoS One; 2014; 9(6):e100429. PubMed ID: 24971511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer.
    Elias EV; de Castro NP; Pineda PH; Abuázar CS; Bueno de Toledo Osorio CA; Pinilla MG; da Silva SD; Camargo AA; Silva WA; E Ferreira EN; Brentani HP; Carraro DM
    Oncotarget; 2016 Nov; 7(46):75672-75684. PubMed ID: 27708222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
    Verschuur-Maes AH; de Bruin PC; van Diest PJ
    Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
    Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.